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Available online 2 May 2008The full-lengthhepatitisC virus (HCV) JFH1genome (genotype2a) producesmoderate titers of infectious particles
in cell culture but the optimal determinants required for virion production are unclear. It has been shown that
intragenotypic recombinants encoding core toNS2 from J6CF in the context of JFH1 aremore robust in the release
of viral particles. To understand the contributions of structural and nonstructural genes to HCV replication
potential and infectivity, we have characterized intragenotypic recombinant genotype 2a viruses with different
portions of the J6 isolate engineered into the JFH1 infectious clone. All genomes produced high levels of
intracellular HCV RNA and NS3 protein in Huh-7.5 transfected cells. However, JFH1 genomes containing J6
sequences from C to E2 (CE2) or C to p7 (Cp7) secreted up to 100-fold more infectious HCV particles than the
parental JFH1 clone. Subsequent infection of naive Huh-7.5 cells with each of the J6/JFH1 recombinants at a
multiplicity of infection of 0.0003 resulted in high viral titers only for CE2 and Cp7 viruses. Comparison of virion
production by the Cp7 J6/JFH1 recombinant to previously described J6/JFH1 recombinants showed ﬂexibility of
the chimeric junction. Moreover, NTRNS2 a chimeric virus equivalent to the previously reported FL-J6/JFH
chimera, showed a 10-fold enhancement of virus titers compared to CNS2. NTRNS2 differs from CNS2 by three
nucleotide differences residing in the 5′ NTR and core coding sequence and all three nucleotide changes were
necessary for increased virion production. Importantly, cells producing Cp7 virus showed increased apoptosis
comparedwith JFH1, an effect correlatingwith virionproduction. These studies begin to unravel requirements for
robust virus replication and the relationship between increased virion production and host cell viability.





Hepatitis C virus (HCV) infection currently affects approximately
170 million people worldwide and is resolved by only a minority of
patients (1999; Wasley and Alter, 2000). The chronic viral infection
frequently progresses to end-stage liver disease, cirrhosis and in some
cases, to development of hepatocellular carcinoma (Alter et al., 1999;
Alter et al., 1992). There is no therapeutic or prophylactic vaccine
available for HCV and the only effective antiviral therapy, interferon
and ribavirin, produces sustained viral clearance in less than 50% of
treated patients (Reichard et al., 1997).
A noteworthycharacteristic of theHCVgenome, a plus-strandRNAof
~9.6 kb, is its genetic diversity (Lindenbach and Rice, 2005; Moradpour
et al., 2007). HCV isolates have been classiﬁed into six major genotypesedicine, 954 Gatewood Road,
ui).
l rights reserved.(from 1–6) and multiple subtypes (a,b,c, etc.). In infected individuals,
HCV exists as quasispecies of closely related genomes (Bukh et al.,1995).
A number of studies have suggested that the outcome of HCV infection
aswell as the response to interferon treatmentdepends on the genotype
or quasispecies with which the patient is infected. However, it is not
clear how subtle differences in the HCV genome affect viral replication,
infectivity and host response (Sakai et al., 2007).
Until recently, the only available system to study the replication cycle
of HCV was the subgenomic replicons that were adapted for efﬁcient
RNA replication in vitro (Blight et al., 2000; Lohmann et al., 1999).
However, full-length genomes containing cell culture-adaptive muta-
tions did not produce infectious virus particles in culture and were
severely attenuated in vivo (Bukh et al., 2002). These observations led to
the hypothesis that mutations that enhance RNA replication may have
deleterious effects onvirionproduction. In 2003, Kato et al. reported that
a subgenomic replicon derived from JFH1 cDNAdid not require adaptive
mutations for efﬁcient replication in cell culture (Kato et al., 2003a). JFH1
is an HCV isolate of genotype 2a (GT2a) obtained from a patient with
fulminant hepatitis (Kato et al., 2001). For reasons that are still not
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moderate titers of infectiousparticles in cell culture (Wakita et al., 2005).
We sought to exploit the use of synthetic chimeric viruses to map
the functional regions of HCV using viruses with different phenotypes.
The infectious clone pJ6CF encodes the consensus polyprotein of HCV
strain HC-J6 (CH) that belongs to genotype 2a, as does JFH1, but J6 does
not replicate in the hepatoma cell line Huh-7.5 (Yanagi et al., 1999).
Chimeric clones have recently been reported in which the structural
region, p7, and NS2 of the JFH1 genome has been replaced with the
analogous region from clones with the same or different genotypes
(Gottwein et al., 2007; Lindenbach et al., 2005; Pietschmann et al.,
2006; Yi et al., 2007). Intragenotypic chimeric viruses in which the
structural region, p7 and a portion of NS2 fromHCV JFH1was replaced
with the corresponding region from the infectious clone pJ6CF derived
from the HCV strain HC-J6(CH), exhibited enhanced RNA replication
and also secreted more infectious virus (Pietschmann et al., 2006).
This indicated that the structural region, p7 or NS2 might inﬂuence
the efﬁciency of HCV replication and virus production. Despite
multiple efforts (Lindenbach et al., 2005; Pietschmann et al., 2006),
it is still not knownwhich regions of the JFH1 genome play a role in its
ability to facilitate viral particle secretion, although a recent report
found that the JFH1 protease and polymerase are essential for
replication of J6/JFH1 recombinants (Murayama et al., 2007). Recently,
it was also shown that speciﬁc nucleotide changes in the structural
region of JFH1 increased virion production (Delgrange et al., 2007).
The present work describes the generation of chimeric JFH1 based
viruses, with structural and non-structural genes from the HCV strain
J6, to optimize virion production. The intragenotypic J6/JFH1 viruses
were compared in terms of intracellular replication and infectious
virus production and we report here a chimeric virus that robustly
produces infectious virus while simultaneously slowing the growth
and increasing the number of apoptotic Huh-7.5 transfected cells.
Results
Construction of intragenotypic J6/JFH1 recombinants
Our goal was to better understand the relative contribution of the
HCV genome structural and non-structural regions in replication and
virion production. Speciﬁcally, we studied the effects of exchanging
intragenotypic E2, p7, NS2 and NS3 proteins on viral replication and
infectivity. To this end, four intragenotypic recombinants were gen-
erated inwhich sequences from the core to part of the protease domain
of NS3 protein of the JFH1 clone were replaced with the analogous
region derived from HCV J6, also genotype 2a (Yanagi et al., 1999)
(Fig. 1A). These recombinants, designated CE2, Cp7, CNS2 and CNS3
comprise J6 genes from core (from amino acid #33) to the C terminal
end of E2, p7, NS2, respectively, or to the N-terminal portion of
NS3 (including amino acid #79 of NS3). These J6/JFH1 recombinants
allowed us to examine the relative contribution of each protein to
replication and virus production.
Replication of intragenotypic J6/JFH1 HCV chimeras
In vitro transcribedRNAswere transfected intoHuh-7.5 cells,which
are highly permissive for HCV replication (Blight et al., 2000). The
wild type JFH1 genome and the replication defective mutant genome
GND served as positive and negative controls, respectively (Wakita
et al., 2005). Replication was monitored at multiple time points after
transfection by examining viral protein expression using western
blotting for NS3. As shown in Fig. 1B, JFH1 and each of the J6/JFH1
genomes expressed NS3 except, as expected, GND. As observed in
Fig. 1B all chimeras showed similar viral protein levels at days 2 and 5
post-transfection, but by day 7 levels of NS3 increased while host cell
protein β-actin levels decreased in cells transfected with CE2 and Cp7
clones.Production of J6/JFH1 chimeric infectious virus
The contribution of the HCV structural proteins to virus assembly
and egress is measured by the efﬁciency of secretion of infectious viral
particles. A comparative short and long term quantitative and kinetic
analysis of infectious particles released in the supernatant was per-
formed. Viral titers were determined by 50% tissue culture infectivity
dose (TCID50) at the indicated time points after transfection. The
amount of infectious virus released varied among the different J6/JFH1
recombinants when analyzed for 96 hours post-transfection (Fig. 1C).
Chimeric viruses Cp7 (4.6 log TCID50/ml) and CE2 (4.2 log TCID50/ml)
showed a 100-fold increase in the amount of infectious virus released
in the supernatant when compared to the wild-type JFH1 (1.8 log
TCID50/ml). Our results conﬁrm the observation that NS2 is important
for virus production and release, since the only difference between the
Cp7 and CNS2 is that in the Cp7 virus NS2 belongs to the parental JFH1
genome. Moreover, these data show that for each intragenotypic re-
combinant, J6 structural sequences increase virus release compared to
the parental JFH1 clone and that, similar to Pietschmann et al. (2006),
virus production can be increased substantially by fusing the pJ6CF
structural sequences at or close to the p7-NS2 cleavage site.
Temporal analysis of infectious virion production revealed a
decrease in viral titers for each chimera over time (Fig. 1D). For each
recombinant, virus production peaked between day 2 and 5 post-
transfectionwith log TCID50/mL values of 4.8 for CNS2 and Cp7, 4.5 for
CE2, 3.8 for CNS3, and 2.8 for JFH1. JFH1 viral titers decreased rapidly,
and were undetectable by day 21. Although the reduction in the level
of secreted virus was delayed for CNS2 and CNS3, by day 35 post-
transfection no infectious viral particles could be detected in the
supernatants of cells transfected with these chimeras. At later time
points (day 77) only Cp7 could be detected in the supernatants of Huh-
7.5 transfected cells (data not shown).
CE2 and Cp7 recombinant J6/JFH1 viruses are more infectious in vitro
Naive Huh-7.5 cells were infected with the supernatants of cells
transfectedwith thedifferent chimeras todeterminewhether therewere
differences in the infectivity of the secreted virus particles. Supernatants
of cells transfected with JFH1, GND and the different J6/JFH1 constructs
were harvested on day 3 post-transfection. After determining the viral
titers, naive Huh-7.5 cells were infected with recombinant virus at a
multiplicity of infection (m.o.i.) of 3×10−4. This m.o.i. was chosen to
normalize initial infection to JFH1 that showed a maximum viral titer
of 2.8 log TCID50/ml. At the indicated time points following infec-
tion, supernatants were collected for viral titer determination (Fig. 1E).
Importantly, viral infectivity determined in four independent low m.o.i.
inoculations andmeasured by TCID50/ml was only evident from the CE2
and Cp7 viruses (Fig. 1E), with both establishing a robust infection
yielding viral titers of 104–105 TCID50/ml of culture supernatant.
Comparison of infectivity and ﬂexibility of chimeric junctions
Three intragenotypic chimeric viruses expressing the structural
region of the pJ6CF clone in the context of JFH1 have been previously
described (Lindenbach et al., 2005; Pietschmann et al., 2006). Chimeric
virus FL-J6/JFH (Lindenbach et al., 2005) contains part of the 5′ NTR
region, core, E1, E2, p7 andNS2 from thepJ6CF clone in the context of the
JFH1 genome. For comparison with Cp7 virus, the most efﬁcient of our
J6/JFH1 viruses, we constructed an equivalent chimeric virus, NTRNS2.
We also constructed a chimeric virus CNS2C3 inwhich core through the
ﬁrst transmembrane domain of NS2 from JFH1 were replaced by the
corresponding region from J6CF. This construct is similar to the J6/C3,
and a third construct, CNS2, is similar to the construct J6/C6. Both J6/C3
and J6/C6 were previously reported to be more efﬁcient than JFH1
(Pietschmann et al., 2006). The kinetics of the release of infectious virus
by the chimeric viruses Cp7, CNS2, CNS2C3andNTRNS2, representing all
Fig. 1. Replication and protein production of chimeric J6/JFH1 virus. (A) Organization of full-length HCV constructs. Four J6/JFH1 infectious clones were developed by swapping
regions from Core to either E2, p7, NS2 or NS3 of the JFH1 genomewith the corresponding region of the J6 genome to create CE2, Cp7, CNS2 and CNS3 recombinants, respectively. HCV
J6 strain sequences are represented in gray while JFH1 sequences are in white. Ten micrograms of in vitro transcribed RNA were electroporated into 8×104 Huh-7.5 cells (B)
Intracellular protein production as measured byWestern blot analysis. Detection of HCV NS3 antigen in transfected Huh-7.5 cells byWestern blot analysis. Cell lysates were prepared
and viral and cellular proteins were detected using anti-NS3monoclonal antibody and anti-β-actin at days 2,5,7,14 and 35 post-transfection. (C) Short term and (D) long term kinetics
of chimeric infectious virus particle release in the supernatant (log10 TCID50/ml). The data shown in Fig. 1C are a collection of three independent transfections with standard error of
mean and 1D is a representative of three independent experiments. Supernatants were harvested at the indicated time points, serially diluted 10-fold and used to inoculate naive
Huh-7.5 cells. The viral titers were determined 3 days post infection by immunohistochemistry using monoclonal anti NS5A antibody and by calculating tissue culture infection dose
at which 50% of the wells were positive for viral antigen. (E) Kinetics of recombinant chimeric virus infection in naive Huh-7.5 cells. Naive Huh-7.5 cells were inoculated at an m.o.i. of
3×10−4 with supernatants of day 3 cultures post-transfection. Infectious virus in the supernatants (log10 TCID50/ml) was determined by IHC using anti-NS5Amonoclonal antibody at
the indicated time points. CNS2, CNS3, GND and JFH showed no infectivity with symbols all overlapping. The data shown in Fig.1E are a collection of four independent infections with
standard error of the mean.
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reported to date, were compared (Fig. 2A). Supernatants of transfected
cells were collected daily for four days and the infectious virus was
quantiﬁed. As shown in Fig. 2B, the amount of infectious virus secretedin the supernatant of Huh-7.5 cells electroporated with the chimeric
RNA transcripts is similar after 24 h post transfection, but after 96 h Cp7
and CNS2C3 are most robustly producing virus. The high titer produced
early by Cp7, CNS2C3 and NTRNS2 chimeric viruses indicates that initial
Fig. 2. Virion production by different chimeric constructs. (A) Constructs that are equivalent to the previously reported NTRNS2 and CNS2C3 are shown. (B) In order to compare their
ability to produce infectious virions, supernatants were collected and infectivity quantiﬁed by IHC assay (log10 TCID50/ml). Signiﬁcant differences were observed in levels of infectious
virus produced by NTRNS2 and CNS2 96 h post transfection (pb0.05). The data shown in Fig. 2B are a collection of at least three independent transfections with standard error of the
mean.
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over point between pJ6CF and JFH1. In agreement with the results
reported by Pietschmann et al. (Pietschmann et al., 2006) CNS2 virus
yields were approximately 10-fold lower than CNS2C3 at 72 h post-
transfection. This difference became more pronounced (~100-fold) at
96 h post-transfection.
Single mutations in the capsid coding sequence do not affect infectious
particles production
Surprisingly, NTRNS2, which is equivalent to FL-J6/JFH reported by
Lindenbach et al. (Lindenbach et al., 2005), showed differences after
two days post transfection in terms of virion production when com-
pared to CNS2. The differences in sequence between CNS2 andNTRNS2
comprise one nucleotide in the 5′ NTR (C301U) and two in the core
region: G398C results in an amino acid change (E20Q) whereas C412U
does not lead to an amino acid change (Fig. 3A). Residue Q20 is present
in J6 (genotype 2a) as well as in other strains of genotype 1a,1b, 2f and
2e. Nucleotide position 301 in the 5′ NTR is in domain IIIe of the IRES
element of HCV and has been reported to interact with the 40S
ribosomal subunit (Spahn et al., 2001) while the other two changes fall
in a loop of secondary structure fromnucleotide 387 to 424 (McMullan
et al., 2007). Both generate changes in the amino acid sequence of the
alternative reading frame (ARF) that results from a+1 frameshift (Baril
and Brakier-Gingras, 2005). The changes in the ARF are G398C (H→Q)
and C412U (S→F). In terms of RNA secondary structure, change G398C is
located in a bulge in stem loop V (SLV) and the change C412U disrupts a
C–G base pair interaction on SLV (Tuplin et al., 2002) (Fig. 3A). Since it
has been previously reported that speciﬁc mutations in JFH1 core
protein are essential for infectious virus production (Delgrange et al.,
2007; Murray et al., 2007), we decided to assess the contribution of
these three mutations on initial translation, subsequent replication
capacity and virion production. To deﬁne the mechanism responsible
for the observed difference between CNS2 and NTRNS2 we developed3 bicistronic genomes (Fig. 3B) in which the 5′ UTR and the ﬁrst 33
amino acids of core protein are fused with Gaussia luciferase protein
(Gluc). In these bicistronic constructs, Gluc is translated from the HCV
IRES while in the second cistron, the EMCV IRES initiates the trans-
lation of the HCV polyprotein (on the highly efﬁcient Cp7 backbone) at
the N-terminus of core. This strategy allows the study of the HCV IRES
efﬁciency independent of replication by determining RLU activity at
early time points (Gluc will be generated via translation of the input
RNA and subsequently detected andmeasured in the supernatant) and
replication capacity of the genomes by assessing RLU at later time
points (replication of the input RNA will continue to generate more
Gluc thus leading to an increase as compared to the replication de-
fective GND control). As shown in Fig. 3C, there were no differences
in translation efﬁciencies between CNS2/Gluc/Cp7, NTRNS2/Gluc/Cp7
and the negative control NTR/NS2/Gluc/GND. In terms of replication,
both constructs were able to replicate above the levels of the rep-
lication defective clone GND (Fig. 3D). To further investigate the effects
of these mutations on virion production, we introduced the three
individual mutations in the context of the CNS2 monocistronic par-
ental genome. Despite the fact that there were signiﬁcant differences
between CNS2 and NTRNS2 (pb0.05), there were not signiﬁcant dif-
ferences in terms of virion production 96 h post transfection between
the three mutants or the parental CNS2 and NTRNS2 parental clones
(Fig. 3E).
Recombinant Cp7 J6/JFH1 virus affects cell division of transfected Huh-7.5
cells
We observed that Huh-7.5 cells transfected with RNA of the Cp7
construct consistently grew slower as compared to cells transfected
with JFH or GND. Since Cp7 produced higher viral titers compared
with JFH1, we sought to further characterize the effect on host cell
growth. Uninfected Huh-7.5 cells were electroporated with in vitro
transcribed RNA from JFH1, Cp7 and GND. Measurement of attached
Fig. 3. Single mutations in the capsid coding sequence do not affect infectious particle production. (A) Three nucleotide differences between CNS2 and NTRNS2 J6/JFH1 viruses are
shown. The ﬁrst nucleotide difference is in the IRES element of the 5′NTR region (C301U). In CNS2 there is a G–C pair in stem loop III (SLIII) while in NTRNS2 there is a disruption of this
base pairing. The other two differences are in the core protein both in stem loop V (SLV): G398C results in an amino acid change (E20Q) whereas C412U does not result in an amino acid
change but causes disruption of the Watson–Crick base-pairing. (B) A schematic representation of the full-length bicistronic Gluc reporter plasmids used to analyze the effect of the
mutations. The plasmids contain Gluc under the control of the HCV IRES and the Cp7 HCV chimeric genome downstream of EMCV IRES. Bicistronic genomes with mutations in the
IRES and core sequence are indicated. (C) Translation and (D) replication of the bicistronic reporter viruses was assessed by transfection of Huh-7.5 cells with 10 μg of in vitro RNA
transcribed biscistronic genomes. Supernatants were harvested and assayed by luciferase activity in triplicates (labeled as log10 Relative Luciferase Units, RLU) at the indicated time
points post electroporation. The levels of Gaussia luciferase secreted during the ﬁrst 8 h post transfection are due to translation of the input RNAwhile the amounts produced 24–96 h
post transfection are due to replication of the full-length bicistronic Gluc reporter RNA. (E) Modiﬁcations in the 5′UTR and core coding sequencewere engineered in the context of the
CNS2 parental virus to compare their capacity to produce infectious virions. Supernatants were harvested and virus quantiﬁed infectivity by IHC assay (log10 TCID50/ml) at the
indicated time points. The data shown in Fig. 3E are a collection of seven independent transfections with standard error of the mean. Amounts of secreted virus in cells transfected
with NTRNS2 were signiﬁcantly higher than CNS2 (asterisks indicate pb0.05) 24, 48 and 96 h post transfection.
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transfected with Cp7 as compared to those transfected with JFH1 or
GND (Fig. 4A). To determine whether this difference was secondary to
reduced cell division or increased cell death, cells were stained 72 h
after transfection with carboxyﬂuorescein succinimidyl ester (CFSE),
which is partitioned equally among daughter cells with each cell
division. At the indicated time points, cells were analyzed by ﬂowcytometry. By day 8, cells transfected with Cp7 showed a signiﬁ-
cantly slower rate of cell division (MFI 595) when compared to those
transfected with JFH1 (MFI 172) and GND (MFI 186) (Fig. 4B). These
differences remained signiﬁcant until day 18 after electroporation
(Fig. 4C). High intracellular viral replication and virion release may
play an important role in the reduced cellular division of Cp7 trans-
fected cells. To conﬁrm that infectious virus was being secreted, viral
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was secreted at day 8 in cells transfected with Cp7 (4.1 log TCID50/ml)
when compared to JFH1 (1.8 log TCID50/ml). By day 18, there was a 1.5
log lower titer of virus released by cells transfected with JFH1 as
compared to Cp7 (Fig. 4D).
Cp7 replication induces apoptosis in Huh-7.5 cells
The diminution in cell division could be secondary to virus in-
duced cell cycle arrest or apoptosis. The cells transfected with JFH,
Cp7 and GND were stained with Annexin-V at days 3, 8 and 18 after
electroporation. As shown in Fig. 4E, JFH and Cp7 transfected cells
appeared to be undergoing apoptosis as indicated by Annexin V
staining at day 3 (11.8% and 16.98% respectively) and day 8 (6.42% and
12.91%, respectively) post transfection. By day 18 only Cp7 trans-
fected cells showed increased percentage of apoptotic cells (4.20%)
compared to the background percentage of apoptosis in control
GND (1.73%) transfectedHuh-7.5 cells. Since thepresence of hypodiploid
nuclei is an indicator of apoptosis, we additionally used ﬂow cytometric
analysis of propidium iodide stained cells and demonstrated that JFH,
Cp7 or GND transfected cells were not arrested in a particular phase of
cell cycle (data not shown). However we observed that the percentage
of hypodiploid cells increased from 7% to almost 20% at day 8 in Cp7
while remainingunchanged for JFH1andGND transfected cells (data not
shown).
Discussion
In this study we described intragenotypic JFH1-based recombi-
nants capable of assembling and releasing infectious viral particles
with greater efﬁciency than the parental JFH1 genome. Through com-
parison of the known intragenotypic recombinants reported to date,
our results conﬁrm previous observations that intragenotypic J6/JFH
recombinants including CNS2 of J6 efﬁciently produce virus (Gottwein
et al., 2007; Pietschmann et al., 2006; Yi et al., 2007) but importantly,
extend these observations to include more efﬁcient genomes that
include only CE2 or Cp7 of J6 and demonstrate decreased cell viability
under conditions of high virus production. It is interesting to note that
in the study described here, the intracellular accumulation of the NS3
protein (Fig. 1B) was notably greater during the ﬁrst 14 days after
transfection of cellswith chimeric CE2 and Cp7, the two constructs that
produced the highest levels of infectious virus (Figs. 1C and D), com-
pared to the other chimeras. A recent study byYi et al. suggests that the
intracellular accumulation of core protein correlates closely with virus
production (Yi et al., 2007). Although pulse chase studies are required
to assess stability of the viral proteins, the authors speculated that the
core protein might be stabilized by being packaged into nascent viral
particles (Yi et al., 2007).
In our studies of virus release, CE2 and Cp7 robustly secrete in-
fectious virus into the supernatants, followed by CNS2 and CNS3 with
similar infectious release kinetics and by JFH1, for which titers are as
low as 2 log TCID50/ml (Figs. 1C and D). Structural sequences from J6CF
increased the efﬁciency of viral production, as reported by Pietsch-
mann et al. (Pietschmann et al., 2006), indicating that J6 proteins may
have a fundamentally better potential for virion assembly and release.Fig. 4. Recombinant virus Cp7 reduces proliferation of Huh-7.5 cells. Cells were electroporated
the indicated time points (A). Cells were CFSE labeled two days post transfection. At days 3, 8
bars represent means and standard deviation of four independent transfections. B) Recombi
slower rate of CFSE dilution. The numbers in each histogram represent the mean ﬂuoresce
decreases geometrically by a factor of two and appears as uniformly spaced clusters on a log s
of four separate experiments. (D) Time course of infectious JFH, Cp7 and GND virus released
(E) Cp7 induces apoptosis in Huh-7.5 cells as indicated by the increase in the percentage of An
stained with Annexin V-APC at days 3, 8 and 18. By day 3 there was a signiﬁcant increase
transfected with the GND negative control (pb0.005). At day 8 and 18, Cp7 transfected ce
parental JFH1 and the GND control (pb0.005 and pb0.05, respectively). The columns and bAs deduced from these results, when NS2 is derived from the same
isolate as the nonstructural proteins, the ability to secrete infec-
tious virus into the supernatants is enhanced. Recent studies have
additionally reported that when the C-terminal portion of the NS2
is derived from the JFH1 sequence, it is more efﬁcient in producing
infectious particles (Pietschmann et al., 2006; Yi et al., 2007). Con-
sistent with replacing JFH1 sequence with J6 sequence, studies of
limited mutations in the structural proteins of JFH1 have shown that
they actually improve virus production (Delgrange et al., 2007). Fur-
thermore, intergenotypic recombinants acquire compensatory muta-
tions in p7, NS2, NS3, and NS5A that appear to facilitate the release of
infectious viral particles (Gottwein et al., 2007; Yi et al., 2007).
In our study, long term kinetic analysis of viral particle release
showed a reduction of viral titerswith time (Fig.1D). This reductionmay
be due to the selection of cells resistant to HCV infection thatmight have
been present in the Huh-7.5 cell line or that emerge during the HCV
infection due to the reduction of CD81 expression (Koutsoudakis et al.,
2007; Morikawa et al., 2007; Tscherne et al., 2007). Indeed, this phe-
nomenon has previously been observed in Huh-7.5 cells transfected
with JFH1 inwhich levels of secreted virus varied and intracellular HCV
RNA levels ﬂuctuated for at least 6 months (Zhong et al., 2006). An
important observation is that Cp7 infected cells continued secreting
virus during the course of the experiment whereas the levels decreased
in Cp7 transfected cells. One possible explanation is that the appearance
of resistant cells is perhaps delayed, in cells infected compared to those
transfected, since levels of secreted virus peaked at day 7 post-infection
whereas the same viral titers (4.5 log TCID50/ml for Cp7 and 3.5 log
TCID50/ml for CE2) are reached at day 2 in transfected cells (Figs. 1C
and E). At lowm.o.i., only infectivity of CE2 and Cp7 could be recovered
conﬁrming the observation that these viruses are more infectious when
compared to the other J6/JFH1 chimeras (Fig. 1E). The lack of viral
particles released into the supernatants of cells infectedwith JFH1, CNS2
and CNS3 virusesmay be attributed to the conditions of the infection. At
very low m.o.i., necessitated by the low titer JFH1, (0.0003 TCID50/cell)
levels of replication may not be sufﬁcient to produce detectable levels
of infectious virus in Huh-7.5 cells and active infection of naive cells is
consequently not maintained.
Others have reported the propagation and passage of JFH1 with-
out loss of infectivity in Huh-7.5.1 cells (Zhong et al., 2005, 2006).
Zhong et al. reported that JFH1 produced high infectivity titers (105–
106 ffu/ml) within a few days after infection of naive Huh-7.5.1 at an
m.o.i. of 0.002 (Zhong et al., 2005) and 0.01 (Zhong et al., 2006). Since
Huh-7.5.1 cells were derived from the Huh-7.5 GFP-HCV replicon cell
line I/5A-GFP6 (Moradpour et al., 2004) andwere curedwith IFN-γ to
eliminate the replicon (Zhong et al., 2005), it is possible that Huh-
7.5.1 are more amenable to infection with HCV than Huh-7.5 cells. It
is however more likely that the high titers were achieved with pas-
saged virus that contained adaptive mutations rather than unmodi-
ﬁed JFH1 from transfection supernatant.
The lack of viral particle production from CNS2 infected cells
(Fig. 1E) suggests that replacement of JFH NS2 with J6CF sequences is
detrimental for virus production at low multiplicity of infection. Pre-
vious reports suggest that themost appropriate crossover site in terms
of better infectivity is at the transmembrane domain-1 (TMD1) of NS2
(Pietschmann et al., 2006). When we compared J6/C3 (crossover sitewith in vitro transcribed RNA of JFH, Cp7 and GND andwere trypsinized and counted at
and 18 post transfection cells were trypsinized and analyzed by FACS. The columns and
nant virus Cp7 retards proliferation of transfected Huh-7.5 cells as demonstrated by the
nce intensity (MFI) of the cells at the indicated time points. After one division the MFI
cale. (C) MFI of cells transfected with JFH1, Cp7 and GND. Data shown are representative
into supernatant (log10 TCID50/ml) of RNA transfected and CFSE labeled Huh-7.5 cells.
nexin-V positive cells. Huh-7.5 transfectedwith JFH1, Cp7 and GNDwere trypsinized and
in the percentage of apoptosis in cells transfected with JFH and Cp7 compared to cells
lls showed a signiﬁcantly higher percentage of apoptotic cells when compared to the
ars represent means and standard deviation of ﬁve independent transfections.
404 G. Mateu et al. / Virology 376 (2008) 397–407right after the ﬁrst TMD of NS2) to Cp7we did not observe a signiﬁcant
difference between Cp7, CNS2C3 and NTRNS2. In agreement with
the results reported by Pietschmann et al. (2006), our data show
that there is ﬂexibility in the optimal junction for the construction of
chimeric HCV genomes in terms of replication efﬁciency and virus
production.
Studies of the 5′ NTR are complicated since the region is known
to contain both translation and replication elements (McMullan et al.,
2007; Reusken et al., 2003). Recent studies suggest that numerous
residues in the core protein are essential for infectious virionproduction
(Murray et al., 2007) possibly due to modulation of host cellular func-
tions. In addition, more robust production of HCV particles can be
obtained by introducing a few speciﬁc mutations in the core coding
sequence of JFH1 (Delgrange et al., 2007). We have performed a com-
prehensive analysis of the effects on translation and replication of these
changes in the core protein in the context of an infectious J6/JFH1
bicistronic reporter virus and subsequently analyzed their impact on
virion production by engineering these changes in a monocistronic
chimeric virus.
Measuring Gluc activity over time allowed us to assess differences in
translation and replication efﬁciency determined by the three positions
that distinguish CNS2 and NTRNS2 (Figs. 3C and D). Since therewere no
signiﬁcant differences in translation and replication efﬁciency between
CNS2 and NTRNS2, it is possible that these three mutations may affect
packaging and release of viral particles leading to an increase in virion
production. Although amino acids 15–28 have been reported to be
dispensable for HCV-like particle assembly and morphogenesis (Hour-
ioux et al., 2007), other studies have shown that mutations in the core
regionmight alter RNApackaging, recruitmentof nonstructural proteins
and replication complexes to lipid droplets, virion assembly and mor-
phogenesis (Boulant et al., 2007; Kim et al., 2006; Miyanari et al., 2007;
Rodriguez-Casado et al., 2007) which are critical for the production of
infectious virus. We observed a consistent two fold increase in rep-
lication levels in NTRNS2 when compared with CNS2, although this
difference in replication is not observable in logarithmic scale (Fig. 3D).
However, it is possible that slight differences in replication can cause a
10-fold increase in virion production.
When single mutations were engineered in the context if the CNS2
backbone, they did not recapitulate the increased virion production
observed for the NTRNS2 clone (Fig. 3E). One possibility is that the
combination of mutations is necessary to observe differences in
virus production. Core contains conserved RNA structures involved in
replication as well as a conserved alternative open reading frame
(ARFP) important for HCV replication in vivo and in vitro (McMullan
et al., 2007). The C-terminal portion has been implicated in the pro-
cessing of the core protein from its immature form to the mature form
necessary for particle formation (Kato et al., 2003b). Consistent with
these data, a recent study by Delgrange et al. showed that two changes
in the carboxy terminal region of JFH1 core, implicated in processing
core to its mature form, could improve infectious virus production
(Delgrange et al., 2007). The authors proposed that these mutations
lead to an increase in immature capsid protein (p23) that may be a
necessary component for virion production. Interestingly, the E20Q
amino acidmutationdescribed in our study (Fig. 3A), in addition to two
other mutations described by Kato et al have been identiﬁed as
important residues conferring increase in p23 levels thus potentially
leading to efﬁcient JFH1 particle formation (Kato et al., 2003b).
Interestingly, we observed that the number of Cp7 transfected cells
did not increase with the same rate as JFH1 or GND transfected cells
(Fig. 4A). To assess if these differences were due to cell death or re-
tardation in cell growth we performed CFSE staining of cells. CFSE
staining showed a reduction of cell proliferation in cells transfectedwith
Cp7 (Figs. 4B and C). We could not attribute this phenomenon to cell
cycle arrest at anyof thedistinct phases in the cell cycle, butweobserved
an increased percentage of apoptosis in cells transfected with JFH1 and
Cp7 compared to cells transfected with the GND control (Fig. 4E).Growth ratewas greatly reducedwhen secreted levels of infectious
virus peaked (Fig. 4D). Once the Cp7 extracellular infectious virus
levels declined, approximately four weeks post-transfection (Fig. 1D),
the effect on cell growth retardationwas no longer observed (data not
shown). We hypothesize that Cp7 transfected cells grew more slowly
and underwent apoptosis (Fig. 4E) because high amounts of viruswere
secreted. After three weeks, HCV resistant cells or cells that did not
secrete high amounts of virus emerged, reducing the levels of secreted
virus and allowing increased cell growth. The appearance of HCV
resistant cells after infection with JFH1 virus has been previously
described and it has been shown to be due to the loss or diminution of
CD81 expression in Huh-7.5 and Huh 7 cell lines (Akazawa et al., 2007;
Koutsoudakis et al., 2007; Morikawa et al., 2007; Tscherne et al., 2007;
Zhong et al., 2006). It is also possible that virus variants could have
emerged during the course of the experiment, but this possibility
is still under investigation. This raises the interesting question of
whether there is an emergence of resistant cells in vivo where viral
titers have been reported to be very high.
Although apoptosis plays a central role for the elimination of viral
infections there is controversy about whether HCV infection has pro-
or anti-apoptotic effects in vivo. There have been reports showing that
individual HCV proteins can directly promote or inhibit apoptosis
(Nanda et al., 2006; Saito et al., 2006; Szabo, 2006).More recently there
have been two reports that have used similar newly developed JFH1 in
vitro systems to study viral factors (Sekine-Osajima et al., 2008) and
host cell factors (Zhu et al., 2007) affecting apoptosis. In our report,
apoptosis of an homogeneous cell population depends on robust virus
production. We observed a correlation between particle production,
cell growth arrest and apoptosis.
What actually happens in the liver of a patient infected with HCV is
not known but it is possible that progressive liver damage might not
only be a result of the anti-HCV immune response but also of direct
cytopathic effect in virally infected cells. Some indirect evidence for this
possibility is that liver injury progresses more rapidly in immune
deﬁcient patients than in immune competent HCV infected patients
(Thomas and Seeff, 2005). Our established set of intragenotypic
chimeras that produce infectious viral particles and in particular, our
chimeric virus that comprises sequences from the isolate J6CF from core
to p7 in the context of JFH1, will be helpful in examining further the
effects of viral mutations, host cell growth retardation and apoptosis,
and compensatory changes on infectivity and HCV persistence.
Materials and methods
Cell culture
Huh-7.5 cells (kindly provided by C.M. Rice; (Blight et al., 2002))
were maintained in Dubecco's modiﬁed Eagle medium (DMEM)
containing 10% heat-inactivated fetal calf serum (Atlanta Biologicals)
and incubated at 37 °C, 5% CO2 and 100% relative humidity.
Construction of full-length chimeric genomes
Plasmids pJFH1 and pGND, full-length genotype 2a cDNA clones,
were described previously (Wakita et al., 2005). Plasmid pJ6CF, a full-
length clone of HCV genotype 2a, was previously shown to be infectious
in chimpanzees (Yanagi et al., 1999).
JFHxJ6 CNS3
Plasmid CNS3 was constructed via 3-piece ligation of the 3222-bp
BstZ17I–BbvCI fragment from plasmid pJ6CF, the 6016-bp BbvCI–XbaI
fragment and the 3122-bp XbaI–BstZ17I fragment from pJFH1.
JFHxJ6 CE2
To generate plasmid CE2, two PCR products were produced with
newly introduced restriction sites to facilitate fusion at the junction of
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product containing the core-E2 region of pJ6CF was ampliﬁed with
primer 027HCVC-F (5′-CGTTGGCGGAGTATACTTGT TGCC-3′) and primer
029HCVE2FPCR-R (5 ′ -CTCGCAGCGTGCAAGACGACAAGCT
TCTCCAATGCTGCTTCGGCCTGG-3′). The latter introduces a HindIII re-
striction site (underlined) in the E2–p7 junction. The second PCR prod-
uct comprised the E2–NS3 region of the JFH1 strain and was ampliﬁed
using primer 030HCVE2FPRC-F, complementary to 029HCVE2FPCR-R
(5′-CCAGGCCGAAGCAGCATTGGAGAAGCTTGTC GTCTTGCACGCTGC-
GAG-3′) and 028HCVNS3-R (5′-TACCAAGTCCCCCTCAG CACTCGAGTA-
3′). The two products were gel puriﬁed and fused via PCR using Vent
polymerase (Biolabs) and the primers 027HCVC-F and 028HCVNS3-R.
This fusion product was digested with BstZ17I–NotI (2515-bp) and
ligated with the 6723-bp NotI–XbaI and 3122-bp XbaI–BstZ17I frag-
ments derived from pJFH1 to generate the full-length clone JFHxJ6 CE2.
JFHxJ6 Cp7
A similar approach was used to construct the full-length clone Cp7.
Two PCR products were produced and fused in order to create the
junction between the p7 gene from pJ6CF and the NS2 gene from
pJFH1. Theﬁrst PCRproduct containing the core-p7 region of pJ6CFwas
ampliﬁed with primer 027HCVC-F and primer 031HCVp7FPCR-R (5′-
GTCCGTGCACAGGTGCGTCATACGCGTAAGCCTGTTG GGGCAATGC-3′),
introducing aMluI restriction site (underlined) in the p7-NS2 junction.
The second PCR fragment encoding the NS2 and NS3 genes of pJFH1
was ampliﬁed using the primer 032HCVp7FPCR-F (5′-GCATTGC-
CCCAACAGGC TTACGCGTATGACGCACCTGT GCACGGAC-3′) that is
complementary to 031HCVp7FPCR-R and primer 028HCVNS3-R.
Both products were gel puriﬁed and fused via PCR using primers
027HCVC-F and 028HCVNS3-R. The resulting fragment was gel puri-
ﬁed and digested with BsiWI–NotI (1611-bp) and ligated with the
6723-bp NotI–XbaI fragment derived from pJFH1 and the 4026-bp
XbaI–BsiWI fragment derived from JFHxJ6 CNS3 to generate the full-
length clone JFHxJ6 Cp7.
JFHxJ6 CNS2
To construct clone CNS2, core-NS2 was ampliﬁed from pJ6CF using
035HCVCJ6-F (TCTCGTAGACCGTGCACCATGAGCACAAATCCTAAAC
CTCAAAG) and 036HCVCJ6-R (GGCATAAGCAGTGATGGGAGCGAGAA-
GACTCCACCCCTTG). To join the NS2 gene from pJ6CF with the NS3
gene from pJFH1, a second PCR product was generated using primers
037HCVNS3JFH-F (GCTCCCATCACTGCTTATGCC) and 038HCVNS3JFH-
R (GCTACCGAGGGGTTAAGCACT). Both products were puriﬁed and
fused via PCR using primers 035HCVCJ6-F and 038HCVNS3JFH-R. This
fragment was used in a 3-piece ligation of the 3222-bp BstZ17I–BbvCI
fusion PCR product, the 6016-bp BbvCI–XbaI and the 3122-bp XbaI–
BstZ17I fragment from pJFH1.
Plasmid CNS2C3 was generated by ligation of the 11,258 bp
BsabI–BbvCI fragment derived from the plasmid Cp7 and 1102 pb
fusion PCR product digested with the same enzymes. The fusion PCR
product was generated by fusing one PCR product generated by
amplifying plasmid CNS2 with 027HCV-F and 085JFHJ6NS2C3R 5′-
GAGATAGCACAACCACCACAGAAACCGGCTGAGAAGGGTCTT-3′ and a
second fragment generated by ampliﬁcation of pJFH1 plasmid with
primers 084JFHJ6NS2C3F 5 ′-AAGACCCTTCTCAGCCGGTTT-
CTGTGGTGGTTGTGCTATCTC-3′ and 028HCVNS3-R. All fragments
generated by PCR were veriﬁed by sequencing.
Gluc/Cp7and mutant derivatives
Plasmid GLuc/Cp7 was constructed by a three-piece ligation of two
fusion PCR products. The ﬁrst fusion PCR fragment was generated by
ampliﬁcation of two PCR products with primers 060EcoRT7NTRJFH
and 136PmeIGlucR. The ﬁrst product (463 bp) was ampliﬁed using
primers 060EcoRT7NTRJFH (5′-CCGGAATTCTAATACGACTCACTATA-
GACC-3′) and 135CoreGLucR (5′-GGGCAAACAGAACTTTGACTCCCATG-
TATACTCCGCCAACGATCT-3′) and JFH1 as a template and encodes fromnucleotide 1 to 463 (amino acid 33 of the core protein) of JFH1 plasmid
and the ﬁrst 8 amino acids of Gaussia luciferase (GLuc) encoding
sequence. The second PCR product used for the fusion was generated
by ampliﬁcation of the sequence encoding for Gluc from plasmid
pCMV-Gluc (New England Biolabs) using primers 134CoreGLucF,
complementary to 135CoreGLucR (5′-CAGATCGTTGGCGGAGTATACAT-
GGGAGTCAAAGTTCTG TTTGCC-3′) and 136PmeIGLucR (5′-GTGGTCT-
GTTTAAACTTAGTCACCACCGGCCCCCCT-3′) that introduced a PmeI
restriction site (underlined) in the 3′ end sequence of Gluc gene.
The second fusion PCR product comprised the EMCV IRES sequence
fused with the ﬁrst amino acid of the core protein to part of NS2
from Cp7 and was generated using primers 066EGFPendEMCVSaF
and 057HCVNS2JFHR. The EMCV IRES sequence was ampliﬁed from
the plasmid FL-Neo (kindly provided by CM Rice) using primers
066EGFPendEMCVSaF (5′-GGCATGGACGAGCTCTACAAGTGAGTT-
TAAACA GACCACAACGGT-3′) and 067EMCVendCofJFH (GAGGTTTAG-
GATTTGTGCTCA TTATTATCGTGTTTTTCAAAGG-3′). The PCR fragment
that encodes for theﬁrst amino acid of the core protein of JFH1 strain to
amino acid 890 in NS2 protein (2668 bp) ampliﬁed with primers
068EMCVendCofJFH (5′-CCTTTGAAAAACACGATAATAATGAGCA-
CAAATCCTAAACCT-3′) and 057HCVNS2JFHR (5′-AACACCACACCCGGG-
CAGAATAT-3′).
To generate the full-length Gluc/Cp7 plasmid, the ﬁrst product
(1115 bp) that encoded for the T7 promoter, HCV IRES and Gluc was
digested with EcoRI–PmeI and ligated with the1635 bp-PmeI–BsiWI
fragment derived from the second fusion PCR that comprised the
EMCV IRES fused with the structural region of Cp7 and a 10992-bp
fragment derived from JFH1 digested with EcoRI –BsiWI.
JFH1SphI and mutagenesis
Plasmid JFH1SphI was generated by ligation of 4943-bp frag-
ment generated by digestion of JFH1 with SphI restriction enzyme.
The plasmid was used for mutagenesis using QuikChange® XL Site
Directed Mutagenesis kit (Stratagene, La Jolla, California). Plasmid
C301U JFH1SphIwas generated bymutagensis of JFH1SphIwith primers
122IRESmutF (5′-GTACTGCCTGATAGGGtGCTTGCGAGTGCCCC-3′) and
123IRESmutR (5′-GGGGCACTCGCAAGCACCCTATCAGGCAGTAC-3′),
G398C JFH1SphI with primers 124Core422F (5′-CCAACCGTCGCCCA-
CAAGACGTTAAGTTCA-3′) and 125Core422R (5′-TGAACTTAACGT-
CTTGTGGGCGACGGTTGG-3′) and C412U JFH1SphI with primers
126Core436F (5′-GAAGACGTTAAGTTtCCGGGCGGCGGCC -3′) and
127Core436R (5′-GGCCGCCGCCCGGAAACTTAACGTCTTC-3′).
NTRNS2/Gluc/Cp7 was obtained by ligation of the EcoRI/PmeI
fusion PCR product in which the template for the generation of the
ﬁrst PCR fragment was NTRNS2 plasmid. All constructs were veriﬁed
by DNA sequencing.
RNA synthesis and transfection
Plasmids containing the full-length chimeric HCV cDNA were
linearized by XbaI digestion (Yamazaki et al., 2002) followed by treat-
ment with mung bean nuclease to remove 5′ end overhangs. The
linearized DNA templates were puriﬁed by phenol:chloroform extrac-
tion and ethanol precipitation and resuspended at a ﬁnal concentra-
tion of 1μg/μl. The linearized DNA templates were transcribed with T7
RNA polymerase using a MEGAscript™ T7 kit (Ambion, Austin, TXs)
according to the manufacturer. After transcription, synthesized RNA
was treated with DNAse I, the integrity of the RNA was analyzed by
non-denaturing agarose gel electrophoresis and the yield determined
by spectrophotometry and adjusted to 2 µg/µl. RNA was stored at
−70 °C until electroporation.
Huh-7.5 cells were grown to 60–80% conﬂuence, trypsinized and
washed twice in cold PBS. Cells were resuspended in cold PBS at a
concentration of 2×107 cells/ml, and 0.4 ml aliquots were mixed with
10 µg of in vitro transcribedRNA anddispensed into 0.4 cmGene Pulser
cuvettes (Bio-Rad). Samples were pulsed using an ECM 830 apparatus
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were resuspended in 20 ml of complete growth medium, plated and
incubated at 37 °C, 5% CO2 and 100% relative humidity.
Western blot analysis of HCV proteins
A each time point, cells were washed twice with PBS, lysed with
200 µl of buffer (100 mM Tris, pH 6.8; 20 mM dithiothreitol; 4% (w/v)
SDS; 20% glycerol; 0.2% w/v bromophenol blue) and homogenized by
passing through a 22-gauge needle. Proteins were separed by SDS-
PAGE and transferred to Immobilon-P membranes (Millipore, Bedford,
MA). Membranes were blocked with TBS-T (20 mM Tris, pH 7.4,
150 mM NaCl, 0.1% (v/v) Tween-20) with 5% w/v dry milk and HCV
proteinsweredetectedusing anti-NS3monoclonal antibody (Virostat),
HRP-conjugated secondary antibodies, (Pierce, Rockford, IL) washed
repeatedly with TBS-T and detected using an ECL kit (Amersham, NJ).
Viral titration and immnunohistochemical staining
Naive Huh-7.5 cells were grown in collagen coated 96well plates at
a concentration of 6×103 cells/well and inoculatedwith the samples at
10 fold dilutions in 8 replicates at each dilution in complete growth
medium. After 3 days of incubation, cells were immunostained for
NS5A (Lindenbach et al., 2005). Cell were washed twice with PBS,
ﬁxed for 10 min with methanol (−20 °C), washed twice with PBS and
permeabilized with one wash of PBS–0.1% Tween 20 (PBS-T). Cells
were then blocked for 30 min at room temperature with PBS-T
containing 1% (w/v) bovine serum albumin (BSA) and 0.2% dry skim
milk, followed by blockage of endogenous peroxidase using 3% H2O2
in PBS for 5 min at room temperature. Cells were washed twice with
PBS and once with PBS-T and incubated 1 h at room-temperature with
a 1:200 dilution of supernatants from the 9E10, anti-NS5A antibody
producing, hybridoma (kindly provided by C.M. Rice). After washing
twice with PBS and once with PBS-T, cells were incubated with goat
anti-mouse HRP polymer (ImmPRESS™-Vector Labs) diluted 1:3 in
PBS-T for 30 min at room temperature. Finally, cells were washed as
described above and developed using DAB substrate (Vector Labora-
tories). The viral titers were determined by immunohistochemistry
using monoclonal anti NS5A antibody by calculating tissue culture
infection dose at which 50% of thewells were positive for viral antigen
(Reed and Muench, 1938).
CFSE staining
Seventy-twohours post electroporation supernatantswere collected
and titered and cells were trypsinized, washed twice with PBS and
resuspended at a concentration of 10–15×105 cells/ml. 2 µl of the CFSE
stock solution (5 mM in DMSO) were added in 1 ml of PBS and the
diluted stock was added to 1 ml of the cell suspension (ﬁnal con-
centration of CFSE 5 µM). Cells were labeled for 5 min at room tem-
perature and immediately washed twice with PBS containing 5% FCS.
Cells were counted (3–5×105 cells) and resuspended in 10 ml of MEM
with 10% FCS and distributed in 24 well plates.
Supernatants were collected every 48 h and analyzed for viral
titers and the cells were trypsinized, counted and analyzed using a
FACScalibur cytometer (Becton Dickinson) and FlowJo software (ver-
sion 6.4).
Annexin APC staining
Apoptosis of transfectedHuh-7.5 cellswasdetermined atday3, 8 and
18 post electroporation by staining with Annexin V-APC (BD Pharmin-
gen™, San Diego, CA) according to the manufacturer's instructions and
FACS analysis was carried out on a FACScalibur cytometer. Cells were
washed twice with PBS, counted, adjusted to 1×106 cells, resuspended
in 100 µl of 1X Annexin V binding buffer (10 mM HEPES/NaOH, pH 7.4,140mMNaCl, 2.5 mMCaCl2) with 5 µl of Annexin V-APC and incubated
for 20min in the dark. The percentage of apoptotic cells asmeasured by
ﬂuorescence intensity of Annexin V staining was determined using the
FACScalibur and FlowJo software (version 6.4).
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